|1.||Pontón, José: 2 articles (03/2009 - 12/2006)|
|2.||Foulet, F: 1 article (03/2015)|
|3.||Sitterle, E: 1 article (03/2015)|
|4.||El Anbassi, S: 1 article (03/2015)|
|5.||Merle, J C: 1 article (03/2015)|
|6.||Botterel, F: 1 article (03/2015)|
|7.||Levesque, E: 1 article (03/2015)|
|8.||Concia, E: 1 article (02/2015)|
|9.||Ligozzi, M: 1 article (02/2015)|
|10.||Koncan, R: 1 article (02/2015)|
11/01/2009 - "This study was performed to assess the epidemiology of fungal infections and to determine (1,3)-beta-D-glucan serum concentrations in patients admitted to intensive care units (ICUs). "
11/01/2009 - "Yet, persistently high serum levels of (1,3)-beta-D-glucan in ICU patients may be indicative of invasive fungal infections and warrant additional diagnostic efforts."
11/01/2009 - "Average (1,3)-beta-D-glucan concentrations were significantly higher in the patients with fungal infections compared to group B and group C (median 44 vs. 22 and 12.9 pg/ml, respectively; p<0.001). "
07/01/2009 - "Increased concentration of (1,3)-beta-D-glucan, one of the major components of fungal cell walls, is detected in the serum of systemic fungal infection. "
09/01/2000 - "The Limulus G test, responsive to beta-1,3-D-glucan, is a well-established method for the detection of invasive fungal infection. "
11/01/2014 - "The aim of this study was to evaluate the usefulness of serum (1,3)-beta-D-glucan (BDG) for earlier detection of breakthrough candidemia. "
11/01/2014 - "Serum (1,3)-beta-D-glucan is an inefficient marker of breakthrough candidemia."
03/01/2011 - "Persistence of a positive (1,3)-beta-D-glucan test after clearance of candidemia in hematopoietic stem cell transplant recipients."
08/01/1996 - "To date there is no published data concerning the efficacy of topical beta-1,3-D-glucan in the treatment of solar keratoses. "
08/01/1996 - "The results of this study showed no significant benefit in using beta-1,3-D-glucan gel over placebo in reducing counts of solar keratoses. "
08/01/1996 - "This randomized double-blind prospective pilot study of 20 patients was performed to investigate the efficacy and skin tolerance of beta-1,3-D-glucan gel versus placebo in the treatment of solar keratoses. "
08/01/1996 - "Beta-1,3-D-glucan gel in the treatment of solar keratoses."
07/01/2009 - "Measuring the concentration of (1,3)-beta-D-glucan in tear fluid might be helpful in the diagnosis of mycotic keratitis."
07/01/2009 - "In our study, the concentration of (1,3)-beta-D-glucan was measured in the tear fluid of patients with mycotic keratitis. "
07/01/2009 - "A significant increase in (1,3)-beta-D-glucan was detected in tear samples from patients with mycotic keratitis. "
07/01/2009 - "Increased level of (1,3)-beta-D-glucan in tear fluid of mycotic keratitis."
07/01/2009 - "The concentration of (1,3)-beta-D-glucan in tear fluid collected after scraping the corneal lesions with a tip of glass capillary was 4.4 +/- 1.3, 8.2 +/- 5.2 and >1,000 pg/ml in the control, bacterial ulcer, and mycotic keratitis samples respectively. "
01/01/1999 - "FK 463, a novel (1,3)-beta-D-glucan synthase inhibitor, showed efficacy against azole-resistant Candida albicans in murine experimental disseminated candidiasis. "
03/31/2009 - "Key words used included candidiasis, Candida, diagnosis, biomarkers, antigen, antibodies, DNA, mannan, and beta-1,3-D-glucan. "
|3.||Interferon-gamma (Interferon, gamma)
|6.||Arachidonic Acid (Vitamin F)
|8.||Biological Markers (Surrogate Marker)
|1.||Transplantation (Transplant Recipients)
|2.||Intensive Care (Surgical Intensive Care)